FDA just approved new migraine treatment drug by Eli Lilly
INDIANAPOLIS, Ind. – If you’re one of the 38 million Americans who suffer from migraines, there’s new hope.
The FDA just approved a migraine treatment drug Emgality, made by drug giant Eli Lilly. It is the third medication approved by the FDA this year for the preventative treatment of migraines.
According to a release from Eli Lilly, the drug is a once-monthly, self-administered injection.
The company found in two phase 3 trials that patients on the drug had between a 3.6 and four-day reduction in migraine days per month (to be eligible, patients had to have between four and 14 migraine days per month).
Eli Lilly says the most common side effect of Emgality is injection site pain. It will be available to patients very soon for pickup at retail pharmacies.
Patients with commercial insurance are candidates to receive Emgality for up to 12 months free as part of Lilly’s patient support program.
Until May, there weren’t any drugs available that were originally approved for alleviating migraines, though other treatments – including Botox and anti-seizure medications – have been used. Pain relievers can also help treat some of the symptoms of migraines.